VIVOTIF SUMMARY
Vivotif® (Typhoid Vaccine Live Oral Ty21a) is a live attenuated vaccine for oral administration only. The vaccine contains the attenuated strain
Salmonella typhi
Ty21a (1,2).
Vivotif® (Typhoid Vaccine Live Oral Ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by Salmonella typhi. Routine typhoid vaccination is not recommended in the United States of America. Selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to
S. typhi, 2) persons with intimate exposure (e.g. household contact) to a
S. typhi
carrier, and 3) microbiology laboratorians who work frequently with
S. typhi(7). There is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps.
Not all recipients of Vivotif® will be fully protected against typhoid fever. Vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. The vaccine will not afford protection against species of
Salmonella
other than
Salmonella typhi or other bacteria that cause enteric disease. The vaccine is not suitable for treatment of acute infections with
S. typhi.
|
